Drugs / Sodium 2,2 dimethylbutyrate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01642758 | May → Nov 2012 | beta-thalassemia intermedia | Boston University | Completed | No outcome recorded |
| Phase 2 | NCT01609595 | Mar → Nov 2012 | beta-thalassemia intermedia | Boston University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sodium 2,2 dimethylbutyrate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01642758 ↗ |
| Action | Activate | “which stimulates production of fetal hemoglobin” NCT01609595 ↗ |
| Modality | Small molecule | “Sodium 2,2 dimethylbutyrate (ST20, or HQK-1001) is a small molecule which stimulates production of fetal hemoglobin in nonhuman primates and in human patients in Phase I/II trials.” NCT01609595 ↗ |
| Route | Oral | “Oral capsule” NCT01609595 ↗ |